- Mr. Aurélien Breton, Managing Director, Servier India 

1. What is the biggest opportunity you see for Indo-French business collaboration in the next 5 years? Please let us know how your company/organisation is preparing for it. 

One of the most promising opportunities for Indo-French collaboration in the next five years lies in fostering innovation in healthcare and related technology and leveraging India as a strategic hub for global capability centers and inclusion of indian subjects in clinical trials. India’s vast patient population and evolving healthcare infrastructure, combined with France’s strength in innovation and translational research, present a unique synergy.  

A Healthcare and Life Sciences Committee or Innovation & Technology Committee through IFCCI may offer excellent platforms to deepen Indo-French collaboration in these areas. These forums can foster dialogue around enabling policy, public-private partnerships, and shared infrastructure for R&D and digital health, ensuring both countries move forward together in creating more equitable cancer care. 

2. In today’s evolving global landscape, how are you building resilience and agility in your leadership strategy? 

In Servier, we believe that resilience stems from a clear sense of purpose, and agility from a culture that embraces innovation, accountability, and fast, data-informed decisions.  

With over 20 years of experience in the pharmaceutical industry, our Managing Director, brings deep expertise in driving sustainable growth across emerging markets —including Europe, Eastern Europe, Africa, and now India. We continue to build on this legacy by: 

• Fostering an entrepreneurial mindset across teams  

• Empowering people at all levels to take initiative and act with ownership  

• Embedding analytics in our decision-making, and  

• Encouraging bold but calculated risk-taking to adapt swiftly to changing conditions.  

We view every new chapter as a chance to learn, grow, and make a meaningful impact. In our new journey in Oncology, we move forward with passion, pace, and purpose. 

3. With sustainability and innovation now essential to business success, could you share some recent initiatives your company has undertaken in these areas? 

A healthy environment is indispensable for good health. That's why, at Servier, we are committed to addressing climate change and environmental degradation. Our strategy encompasses reducing our greenhouse gas emissions, fostering biodiversity and conserving natural resources and is integrated into every stage of the drug life cycle.  Globally, we have achieved : 

• 42% CO2 emissions, scopes 1 and 2, by 2030 compared with 2021/2022 

• 25% CO2 emissions, scope 3, by 2030 compared with 2021/2022 

• We subscribe to the ten commitments defined by Act4natureinternational 

• Ecodesign for medications and packaging, and the management of waste generated by our activities 

4. As a CEO, how do you view India's role in your global growth strategy and what strategic advantages does the country offer your business or the industry you operate in? 

We are expanding our oncology portfolio from 2024 and strengthening our presence in CMVD and diabetes. In India, we launched our oncology portfolio with drug for Pancreatic cancer last year. We have now introduced targeted therapy for IDH mutated AML and Cholangiocarcinoma – in the first week of June 2025. We also focus on improving product accessibility and take efforts to increase affordability, working closely with healthcare professionals.  

India is home to leading contract manufacturing organizations that consistently deliver high-quality products with faster turnaround times compared to many other regions. Leveraging this strength, we are positioning India as a key export hub, where we develop and manufacture combination therapies, conduct bioequivalence studies, and run clinical trials to serve global markets.  

This transformation aligns with Servier Group’s 2030 ambition. India’s growing healthcare ecosystem, government reforms, and rich talent pool provide a unique opportunity for us to meaningfully address local healthcare challenges while contributing to Servier’s global growth ambition.